<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="715">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151848</url>
  </required_header>
  <id_info>
    <org_study_id>CSTAR-007</org_study_id>
    <nct_id>NCT05151848</nct_id>
  </id_info>
  <brief_title>Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis</brief_title>
  <acronym>ADATOFTAK</acronym>
  <official_title>An Open-labelï¼ŒRandomized Controlled, Multicenter Study of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese SLE Treatment And Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese SLE Treatment And Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective,open-labelled,multi-center,randomized clincial trial.It comapres the&#xD;
      clincal efficiacy and safety of there 2 drugs in the treatment of relapse active Takayasu's&#xD;
      arteritis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 100 active relapse Takayasu's arteritis patients will be enrolled. Patients&#xD;
      are randomized into the adalimubmab treatment group and tofacitinib treatment.Patients will&#xD;
      also be treated with reduced dose of glucocortoid at the same time. The primary end point is&#xD;
      the percentage of patients who are in complete response and maintain in complete response at&#xD;
      week 52.&#xD;
&#xD;
      The efficiacy will be evulated at week 12, 24, 36 and 52. If patient are not respond to one&#xD;
      drug at week 12,then they will be changed to being treated with another intervention.Safety&#xD;
      is also monitored during the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open-label, multicenter,randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients with complete response</measure>
    <time_frame>week 52</time_frame>
    <description>percentage of patients with complete response at week 52</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of patients with partial response</measure>
    <time_frame>week 52</time_frame>
    <description>percentage of patients with partial response at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage with image disease at the end of study</measure>
    <time_frame>week 52</time_frame>
    <description>percentage of patients with stable disease deminstrated by CTA or Doppler at week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>52 weeks</time_frame>
    <description>safety profile of both Adalimumab and Tofacitinib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intervention procedures</measure>
    <time_frame>52 weeks</time_frame>
    <description>percentage who require intervention procedures in both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Takayasu Arteritis</condition>
  <arm_group>
    <arm_group_label>Adalimumab treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab, 40mg subcutaneous injection, every 2 week, for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tofacitinib treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tofacitinib 5mg BID for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab Ab</intervention_name>
    <description>Adalimumab Ab is adminstrated subcutaneouls every other week for 52 weeks</description>
    <arm_group_label>Adalimumab treatment group</arm_group_label>
    <arm_group_label>Tofacitinib treatment group</arm_group_label>
    <other_name>Anjianning</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged between 18-65 years old;&#xD;
&#xD;
          2. Fulfilled the classification criteria of Takayasu's arteritis by ACR 1990;&#xD;
&#xD;
          3. relapsed active TAK: defined by the definition of active disease in the&#xD;
             recommendations released by EULAR in 2018;&#xD;
&#xD;
          4. Patients who signed the informed consent form. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who failed or intolerate to either adalimumab or tofacitinib;&#xD;
&#xD;
          2. patients with severe liver disease defined by the serum ALT or AST elevated more than&#xD;
             2 times the upper limits;&#xD;
&#xD;
          3. not well controlled diabetes;&#xD;
&#xD;
          4. uncontrolled heart failure od renal dysfunction(eGFR&lt;30ml/min);&#xD;
&#xD;
          5. Patients with active infection,including tuberculosis, hepatitis B and C,HIV&#xD;
             infection, bacteria or fungal infection;&#xD;
&#xD;
          6. upper GI bleeding 3 months before enrollement;&#xD;
&#xD;
          7. refractory hypertension;&#xD;
&#xD;
          8. Pregnant or intented to be pregnant 3 months after the trial;&#xD;
&#xD;
          9. Severe coronary artery involvement demonstrated by CTA;&#xD;
&#xD;
         10. severe cranial or cervial or renal artery diseases that need surgery;&#xD;
&#xD;
         11. Patients that should not be included by the investigator. -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaofeng Zeng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xinping Tian, MD</last_name>
    <phone>8613691165939</phone>
    <phone_ext>8613691165939</phone_ext>
    <email>tianxp6@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yunjiao Yang, MD</last_name>
    <phone>8613671313079</phone>
    <phone_ext>8613671313079</phone_ext>
    <email>yangyunjiao81@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lili Pan, MD</last_name>
      <phone>13720021786</phone>
      <email>lilypansxmu@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Taotao Li, MD</last_name>
      <phone>13621314886</phone>
      <email>litaotao789@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The General Hospital of the People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jian Zhu, MD</last_name>
      <phone>13671105096</phone>
      <email>jian_jzhu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Aihua Wan</last_name>
      <phone>13641380248</phone>
      <email>284986094@qq.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yuhua Wang, MD</last_name>
      <phone>18610276177</phone>
      <email>wyhxxtt@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yawen Shen, MD</last_name>
      <phone>13051581579</phone>
      <email>songajulia@163.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Beijing Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteritis</mesh_term>
    <mesh_term>Takayasu Arteritis</mesh_term>
    <mesh_term>Aortic Arch Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

